中华骨与关节外科杂志

参考文献

[1]Bijlsma AY,Meskers CG,Westendorp RG,et al.Chronology of age-related disease definitions:osteoporosis and sarcopenia[J].Ageing Res Rev,2012,11(2):320-324.

[2]NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis,and Therapy,March 7-29,2000:highlights of the conference[J].South Med J,2001,94(6):569-573.

[3]Seriolo B,Paolino S,Casabella A,et al.Osteoporosis in the elderly[J].Aging Clin Exp Res,2013,25 Suppl 1:S27-S 29.

[4]陈蕃.21世纪老龄问题研究[M].北京:宇航出版社,1993.

[5]中华人民共和国国家统计局.中国统计年鉴[M].北京:中国统计出版社,2022.

[6]中国疾病预防控制中心,中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查报告(2018)[M].北京:人民卫生出版社,2021.

[7]Wang L,Yu W,Yin X,et al.Prevalence of osteoporosis and fracture in China:the China osteoporosis prevalence study[J].JAMA Netw Open,2021,4(8):e2121106.

[8]Si L,Winzenberg TM,Jiang Q,et al.Projection of osteoporosis-related fractures and costs in China:2010-2050[J].Osteoporos Int,2015,26(7):1929-1937.

[9]Osnes EK,Lofthus CM,Meyer HE,et al.Consequences of hip fracture on activities of daily life and residential needs[J].Osteoporos Int,2004,15(7):567-574.

[10]Wang O,Hu Y,Gong S,et al.A survey of outcomes and management of patients post fragility fractures in China[J].Osteoporos Int,2015,26(11):2631-2640.

[11]Shapiro J,Bernica J,Hernaez R.Risk of bias analysis of systematic reviews of probiotics for treatment of irritable bowel syndrome[J].Clin Gastroenterol Hepatol,2019,17(4):784-785.

[12]Bergman J,Nordstr?m A,Nordstr?m P.Bisphosphonate use after clinical fracture and risk of new fracture[J].Osteoporos Int,2018,29(4):937-945.

[13]Hopkins SJ,Toms AD,Brown M,et al.Disuse osteopenia following leg fracture in postmenopausal women:implications for hip fracture risk and fracture liaison services[J].Radiography (Lond),2018,24(2):151-158.

[14]Duque G,Troen BR.Understanding the mechanisms of senile osteoporosis:new facts for a major geriatric syndrome[J].J Am Geriatr Soc,2008,56(5):935-941.

[15]丁超,孙强.老年性骨质疏松症相关问题研究进展[J].中国骨质疏松杂志,2016,22(3):372-375.

[16]王洪复.老年性骨质疏松症病理机制与防治原则[J].中华保健医学杂志,2010,12(1):1-4.

[17]王鸥,邢小平.老年性骨质疏松症发病机制及药物治疗进展[J].中国实用内科杂志,2011,31(8):584-586.

[18]Starup-Linde J,Vestergaard P.Management of endocrine disease:Diabetes and osteoporosis:cause for concern?[J].Eur J Endocrinol,2015,173(3):R93-R99.

[19]Feng J,Liu S,Ma S,et al.Protective effects of resveratrol on postmenopausal osteoporosis:regulation of SIRT1-NF-κB signaling pathway[J].Acta Biochim Biophys Sin(Shanghai),2014,46(12):1024-1033.

[20]Orimo H,Nakamura T,Hosoi T,et al.Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary[J].Arch Osteoporos,2012,7(1):3-20.

[21]Schulman RC,Weiss AJ,Mechanick JI.Nutrition,bone,and aging:an integrative physiology approach[J].Curr Osteoporos Rep,2011,9(4):184-195.

[22]Liu X,Wan M.A tale of the good and bad:cell senescence in bone homeostasis and disease[J].Int Rev Cell Mol Biol,2019,346:97-128.

[23]Xiao YZ,Yang M,Xiao Y,et al.Reducing hypothalamic stem cell senescence protects against aging-associated physiological decline[J].Cell Metab,2020,31(3):534-548.e5.

[24]Farr JN,Rowsey JL,Eckhardt BA,et al.Independent roles of estrogen deficiency and cellular senescence in the pathogenesis of osteoporosis:evidence in young adult mice and older humans[J].J Bone Miner Res,2019,34(8):1407-1418.

[25]Farr JN,Xu M,Weivoda MM,et al.Targeting cellular senescence prevents age-related bone loss in mice[J].Nat Med,2017,23(9):1072-1079.

[26]Farr JN,Khosla S.Cellular senescence in bone[J].Bone,2019,121:121-133.

[27]Farr JN,Fraser DG,Wang H,et al.Identification of senescent cells in the bone microenvironment[J].J Bone Miner Res,2016,31:1920-1929．

[28]Liu F,Yuan Y,Bai L,et al.LRRc17 controls BMSC senescence via mitophagy and inhibits the therapeutic effect of BMSCs on ovariectomy-induced bone loss[J].Redox Biol,2021,43:101963.

[29]Li CJ,Xiao Y,Sun YC,et al.Senescent immune cells release grancalcin to promote skeletal aging[J].Cell Metab,2021,33:1957-1973.e6.

[30]Locantore P,Del Gatto V,Gelli S,et al.The interplay between immune system and microbiota in osteoporosis[J].Mediators Inflamm,2020:3686749.

[31]Sato K,Suematsu A,Okamoto K,et al.Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction[J].J Exp Med,2006,203:2673-2682.

[32]Lucas S,Omata Y,Hofmann J,et al.Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss[J].Nat Commun,2018,9:55.

[33]Tyagi AM,Yu M,Darby TM,et al.The microbial metabolite butyrate stimulates bone formation via T regulatory cellmediated regulation of WNT10B expression[J].Immunity,2018,49:1116-1131.e7.

[34]Xie H,Cui Z,Wang L,et al.PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis[J].Nat Med,2014,20:1270-1278.

[35]Zhou YM,Yang YY,Jing YX,et al.BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling[J].J Bone Miner Res,2020,35:978-993.

[36]Esen E,Lee SY,Wice BM,et al.PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling[J].J Bone Miner Res,2015,30:1959-1968.

[37]Esen E,Chen J,Karner CM,et al.WNT-LRP5 signaling induces Warburg effect through m TORC2 activation during osteoblast differentiation[J].Cell Metab,2013,17:745-755.

[38]Yang YY,Zhou YM,Xu JZ,et al.Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via the canonical Wnt/β-catenin pathway[J].J Bone Miner Res,2021,36:1605-1620.

[39]Li GF,Pan YZ,Sirois P,et al.Iron homeostasis in osteoporosis and its clinical implications[J].Osteoporos Int,2012,23:2403-2408.

[40]李光飞,张辉,王爱飞,等.铁蓄积通过干扰Wnt信号通路导致骨质疏松[J].中华内分泌代谢杂志,2019,35:1061-1064.

[41]Yuan Y,Fang Y,Zhu L,et al.Deterioration of hematopoietic autophagy is linked to osteoporosis[J].Aging Cell,2020,19:e13114.

[42]张萌萌,张秀珍,邓伟民,等.骨代谢生化指标临床应用专家共识[J].中国骨质疏松杂志,2020,26(6):781-796.

[43]Vasikaran S,Eastell R,Bruyère O,et al.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment:a need for international reference standards[J].Osteoporos Int,2011,22(2):391-420.

[44]Bauer D,Krege J,Lane N,et al.National bone health alliance bone turnover marker project:current practices and the need for US harmonization,standardization,and common reference ranges[J].Osteoporos Int,2012,23(10):2425-2433.

[45]WPark SY,Ahn SH,Yoo JI,et al.Position statement on the use of bone turnover markers for osteoporosis treatment[J].J Bone Metab,2019,26(4):213-224.

[46]Eastell R,Pigott T,Gossiel F,et al.Diagnosis of endocrine disease:bone turnover markers:are they clinically useful?[J].Eur J Endocrinol,2018,178(1):R19-R31.

[47]Naylor KE,Jacques RM,Paggiosi M,et al.Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis:the TRIO study[J].Osteoporos Int,2016,27(1):21-31.

[48]Eastell R,Krege JH,Chen P,et al.Development of an algorithm for using PINP to monitor treatment of patients with teriparatide[J].Curr Med Res Opin,2006,22(1):61-66.

[49]Genant HK,Cann CE,Ettinger B,et al.Quantitative computed tomography of vertebral spongiosa:a sensitive method for detecting early bone loss after oophorectomy[J].Ann Intern Med,1982,97(5):699-705.

[50]马远征,王以朋,刘强,等.中国老年骨质疏松症诊疗指南(2018)[J].中国骨质疏松杂志,2018,24(12):1541-1567.

[51]《中国定量CT(QCT)骨质疏松症诊断指南》工作组,程晓光,王亮,等.中国定量CT(QCT)骨质疏松症诊断指南(2018)[J].中国骨质疏松杂志,2019,25(6):733-737.

[52]Mann C,Ziegeler K,Mews J,et al.Bone mineral density assessment using iterative reconstruction compared with quantitative computed tomography as the standard of reference[J].Sci Rep,2018,8(1):15095.

[53]Adams AL,Fischer H,Kopperdahl DL,et al.Osteoporosis and hip fracture risk from routine computed tomography scans:the fracture,osteoporosis,and CT utilization study(FOCUS)[J].J Bone Miner Res,2018,33(7):1291-1301.

[54]Engelke K,Adams JE,Armbrecht G,et al.Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults:the 2007 ISCD official positions[J].J Clin Densitom,2008,11(1):123-162.

[55]American College of Radiology.ACR-SPR-SSR practice parameter for the performance of musculoskeletal quantitative computed tomography (QCT) bone mineral density[EB/OL].[2022-08-05].https://www.acr.org/-/media/ACR/Files/Practice-Parameters/QCT.pdf.

[56]李凯,陈捷,赵林芬,等.中国人群定量CT(QCT)脊柱骨密度正常参考值的建立和骨质疏松症QCT诊断标准的验证[J].中国骨质疏松杂志,2019,25(9):12571262,1272.

[57]Cheng X,Zhao K,Zha X,et al.Opportunistic screening using lowdose CT and the prevalence of osteoporosis in China:a nationwide,multicenter study[J].J Bone Miner Res,2021,36(3):427435.

[58]Yuan Y,Zhang P,Tian W,et al.Application of bone turnover markers and DXA and QCT in an elderly Chinese male population[J].Ann Palliat Med,2021,10(6):6351-6358.

[59]Xu XM,Li N,Li K,et al.Discordance in diagnosis of osteoporosis by quantitative computed tomography and dualenergy X-ray absorptiometry in Chinese elderly men[J].JOrthop Translat,2018,18:59-64.

[60]中国营养学会.中国居民膳食指南(2022)[M].北京:人民卫生出版社,2022.

[61]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.

[62]Shi Y,Zhan Y,Chen Y,et al.Effects of dairy products on bone mineral density in healthy postmenopausal women:a systematic review and meta-analysis of randomized controlled trials[J].Arch Osteoporos,2020,15(1):48.

[63]Bristow SM,Bolland MJ,Gamble GD,et al.Dietary calcium intake and change in bone mineral density in older adults:a systematic review of longitudinal cohort studies[J].Eur J Clin Nutr,2022,76(2):196-205.

[64]中国营养学会骨营养与健康分会,中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症患者的营养和运动管理专家共识[J].中华内分泌代谢杂志,2020,36(8):643-653.

[65]Sakhaee K,Bhuket T,Adams-Huet B,et al.Meta-analysis of calcium bioavailability:a comparison of calcium citrate with calcium carbonate[J].Am J Ther,1999,6(6):313-322.

[66]邢小平,母义明.临床路径治疗药物释义·内分泌病与代谢病分册[M].北京:中国协和医科大学出版社,2018.

[67]王琴芳,赵朝伟,杨俊卿.枸橼酸钙治疗骨质疏松症的作用特点[J].中国药业,2003,12(2):77-78.

[68]Min CY,Yoo DM,Choi HG.Associations between physical activity,sunshine duration and osteoporosis according to obesity and other lifestyle factors:a nested case-control study[J].Int J Environ Res Public Health,2021,18(9):4437.

[69]Liu H,Wang G,Wu T,et al.Efficacy and safety of eldecalcitol for osteoporosis:a meta-analysis of randomized controlled trials[J].Front Endocrinol (Lausanne),2022,13:854439.

[70]Xu Z,Fan C,Zhao X,et al.Treatment of osteoporosis with eldecalcitol,a new vitamin D analog:a comprehensive review and meta-analysis of randomized clinical trials[J].Drug Des Devel Ther,2016,10:509-517.

[71]Assantachai P,Chatthanawaree W,Thamlikitkul V,et al.Strategy to prevent falls in the Thai elderly:a controlled study integrated health research program for the Thai elderly[J].J Med Assoc Thai,2002,85(2):215-222.

[72]Minneci C,Mello AM,Mossello E,et al.Comparative study of four physical performance measures as predictors of death,incident disability,and falls in unselected older persons:the insufficienza Cardiaca negli Anziani Residenti a Dicomano Study[J].J Am Geriatr Soc,2015,63(1):136-141.

[73]Peng K,Tian M,Andersen M,et al.Incidence,risk factors and economic burden of fall-related injuries in older Chinese people:a systematic review[J].Inj Prev,2019,25(1):4-12.

[74]Gillespie LD,Robertson MC,Gillespie WJ,et al.Interventions for preventing falls in older people living in the community[J].Cochrane Database Syst Rev,2012,2012(9):CD007146.

[75]Gregson CL,Armstrong DJ,Bowden J,et al.UK clinical guideline for the prevention and treatment of osteoporosis[J].Arch Osteoporos,2022,17(1):58.

[76]Chaplin S.SIGN on managing osteoporosis and fragility fracture prevention[J].Prescriber,2021,32(2):29-32.

[77]Sinaki M.Exercise for patients with osteoporosis:management of vertebral compression fractures and trunk strengthening for fall prevention[J].PM R,2012,4(11):882-888.

[78]Wang Q,Jiang X,Shen Y,et al.Effectiveness of exercise intervention on fall-related fractures in older adults:a systematic review and meta-analysis of randomized controlled trials[J].BMC Geriatr,2020,20(1):322.

[79]Zhao R,Bu W,Chen X.The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions,and differing intervention protocols:a meta-analysis of randomized controlled trials[J].BMC Geriatr,2019,19(1):341.

[80]N?rgaard JE,Jorgensen MG,Ryg J,et al.Effects of gait adaptability training on falls and fall-related fractures in older adults:a systematic review and meta-analysis[J].Age Ageing,2021,50(6):1914-1924.

[81]El-Khoury F,Cassou B,Charles MA,et al.The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults:systematic review and meta-analysis of randomised controlled trials[J].BMJ,2013,347:f6234.

[82]Ong MF,Soh KL,Saimon R,et al.Fall prevention education to reduce fall risk among communitydwelling older persons:a systematic review[J].J Nurs Manag,2021,29(8):2674-2688.

[83]Scott V,Votova K,Scanlan A,et al.Multifactorial and functional mobility assessment tools for fall risk among older adults in community,home-support,long-term and acute care settings[J].Age Ageing,2007,36(2):130-139.

[84]Lachance CC,Jurkowski MP,Dymarz AC,et al.Compliant flooring to prevent fall-related injuries in older adults:a scoping review of biomechanical efficacy,clinical effectiveness,cost-effectiveness,and workplace safety[J].PLo SOne,2017,12(2):e0171652.

[85]Dautzenberg L,Beglinger S,Tsokani S,et al.Interventions for preventing falls and fallrelated fractures in communitydwelling older adults:a systematic review and network meta-analysis[J].J Am Geriatr Soc,2021,69(10):2973-2984.

[86]Hart LA,Phelan EA,Yi JY,et al.Use of fall risk-increasing drugs around a fall-related injury in older adults:a systematic review[J].J Am Geriatr Soc,2020,68(6):1334-1343.

[87]Kohrt WM,Bloomfield SA,Little KD,et al.Physical activity and bone health[J].Med Sci Sports Exerc,2004,36(11):1985-1996.

[88]Kistler-Fischbacher M,Weeks BK,Beck BR.The effect of exercise intensity on bone in postmenopausal women (part2):a meta-analysis[J].Bone,2021,143:115697.

[89]Zhao R,Zhang M,Zhang Q.The effectiveness of combined exercise interventions for preventing postmenopausal bone loss:a systematic review and meta-analysis[J].J Orthop Sports Phys Ther,2017,47(4):241-251.

[90]Babatunde OO,Bourton AL,Hind,et al.Exercise interventions for preventing and treating low bone mass in the forearm:a systematic review and meta-analysis[J].Arch Phys Med Rehabil,2020,101(3):487-511.

[91]Zhao R,Bu W,Chen X.The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions,and differing intervention protocols:a meta-analysis of randomized controlled trials[J].BMC Geriatr,2019,19(1):341.

[92]Pinheiro MB,Oliveira J,Bauman A,et al.Evidence on physical activity and osteoporosis prevention for people aged 65+years:a systematic review to inform the WHOguidelines on physical activity and sedentary behaviour[J].Int J Behav Nutr Phys Act,2020,17(1):150.

[93]Ponzano M,Rodrigues IB,Hosseini Z,et al.Progressive resistance training for improving health-related outcomes in people at risk of fracture:a systematic review and metaanalysis of randomized controlled trials[J].Phys Ther,2021,101(2):pzaa221.

[94]Kemmler W,Shojaa M,Kohl M,et al.Effects of different types of exercise on bone mineral density in postmenopausal women:a systematic review and meta-analysis[J].Calcif Tissue Int,2020,107(5):409-439.

[95]Piercy KL,Troiano RP,Ballard RM,et al.The physical activity guidelines for Americans[J].JAMA,2018,320(19):2020-2028.

[96]Benedetti MG,Furlini G,Zati A,et al.The effectiveness of physical exercise on bone density in osteoporotic patients[J].Biomed Res Int,2018,2018:4840531.

[97]Castellano D,Sepulveda JM,García-Escobar I,et al.The role of RANK-ligand inhibition in cancer:the story of denosumab[J].Oncologist,2011,16(2):136-145.

[98]中华医学会骨质疏松和骨矿盐疾病分会.地舒单抗在骨质疏松症临床合理用药的中国专家建议[J].中华骨质疏松和骨矿盐疾病杂志,2020,13(6):499-508.

[99]Chen Y,Zhu J,Zhou Y,et al.Efficacy and safety of denosumab in osteoporosis or low bone mineral density postmenopausal women[J].Front Pharmacol,2021,12:588095.

[100]Lyu H,Jundi B,Xu C,et al.Comparison of denosumab and bisphosphonates in patients with osteoporosis:a metaanalysis of randomized controlled trials[J].J Clin Endocrinol Metab,2019,104(5):1753-1765.

[101]Wu J,Zhang Q,Yan G,et al.Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis:a meta-analysis[J].J Orthop Surg Res,2018,13(1):194.

[102]Mandema JW,Zheng J,Libanati C,et al.Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis:a doseresponse-based meta-analysis[J].J Clin Endocrinol Metab,2014,99(10):3746-3755.

[103]Li L,Gong M,Bao D,et al.Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis:a reanalysis of the meta-analysis[J].Bone,2020,134:115270.

[104]Bone HG,Wagman RB,Brandi ML,et al.10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOMtrial and open-label extension[J].Lancet Diabetes Endocrinol,2017,5(7):513-523.

[105]Gopaul A,Kanagalingam T,Thain J,et al.Denosumab in chronic kidney disease:a narrative review of treatment efficacy and safety[J].Arch Osteoporos,2021,16(1):116.

[106]Chen CH,Lo WC,Hu PJ,et al.Efficacy of osteoporosis medications for patients with chronic kidney disease:an updated systematic review and network meta-analysis[J].Front Pharmacol,2022,13:822178.

[107]Cummings SR,Ferrari S,Eastell R,et al.Vertebral fractures after discontinuation of denosumab:a post hoc analysis of the randomized placebocontrolled FREEDOM trial and its extension[J].J Bone Miner Res,2018,33(2):190-198.

[108]Tsourdi E,Langdahl B,Cohen-Solal M,et al.Discontinuation of Denosumab therapy for osteoporosis:a systematic review and position statement by ECTS[J].Bone,2017,105:11-17.

[109]Wan Y,Zeng F,Tan H,et al.Cost-effectiveness analyses of denosumab for osteoporosis:a systematic review[J].Osteoporos Int,2022,33(5):979-1015.

[110]Mc Clung MR,Grauer A,Boonen S,et al.Romosozumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2014,370(5):412-420.

[111]李宁,李新萍,杨明辉,等.老年髋部骨折的骨质疏松症诊疗专家共识[J].中华骨与关节外科杂志,2021,14(8):657-663.

[112]Eastell R,Rosen CJ,Black DM,et al.Pharmacological management of osteoporosis in postmenopausal women:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2019,104(5):1595-1622.

[113]Camacho PM,Petak SM,Binkley N,et al.American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update[J].Endocr Pract,2020,26(Suppl 1):1-46.

[114]Kanis JA,Harvey NC,Mc Closkey E,et al.Algorithm for the management of patients at low,high and very high risk of osteoporotic fractures[J].Osteoporos Int,2020,31(1):1-12.

[115]Singh S,Dutta S,Khasbage S,et al.A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis[J].Osteoporos Int,2022,33(1):1-12.

[116]Shen J,Ke Z,Dong S,et al.Pharmacological therapies for osteoporosis:a Bayesian network meta-analysis[J].Med Sci Monit,2022,28:e935491.

[117]Cosman F,Crittenden DB,Adachi JD,et al.Romosozumab treatment in postmenopausal women with osteoporosis[J].N Engl J Med,2016,375(16):1532-1543.

[118]Saag KG,Petersen J,Brandi ML,et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.

[119]Lv F,Cai X,Yang W,et al.Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis:systematic review and meta-analysis[J].Bone,2020,130:115-121.

[120]Body JJ,Bergmann P,Boonen S,et al.Non-pharmacological management of osteoporosis:a consensus of the Belgian Bone Club[J].Osteoporos Int,2011,22(11):2769-2788.

[121]Rondanelli M,Faliva MA,Barrile GC,et al.Nutrition,physical activity,and diet